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Summary
Background Behavioural interventions might improve clinical outcomes in pregnant women who are obese. We aimed 
to investigate whether a complex intervention addressing diet and physical activity could reduce the incidence of 
gestational diabetes and large-for-gestational-age infants.
Methods The UK Pregnancies Better Eating and Activity Trial (UPBEAT) is a randomised controlled trial done at 
antenatal clinics in eight hospitals in multi-ethnic, inner-city locations in the UK. We recruited pregnant women 
(15–18 weeks plus 6 days of gestation) older than 16 years who were obese (BMI ≥30 kg/m²). We randomly assigned 
participants to either a behavioural intervention or standard antenatal care with an internet-based, computer-
generated, randomisation procedure, minimising by age, ethnic origin, centre, BMI, and parity. The intervention was 
delivered once a week through eight health trainer-led sessions. Primary outcomes were gestational diabetes 
(diagnosed with an oral glucose tolerance test and by criteria from the International Association of Diabetes in 
Pregnancy Study Groups) and large-for-gestational-age infants (≥90th customised birthweight centile). Analysis was 
by intention to treat. This trial is registered with Current Controlled Trials, ISCRTN89971375. Recruitment and 
pregnancy outcomes are complete but childhood follow-up is ongoing.
Findings Between March 31, 2009, and June 2, 2014, we assessed 8820 women for eligibility and recruited 1555, with 
a mean BMI of 36·3 kg/m² (SD 4·8). 772 were randomly assigned to standard antenatal care and 783 were allocated 
the behavioural intervention, of which 651 and 629 women, respectively, completed an oral glucose tolerance test. 
Gestational diabetes was reported in 172 (26%) women in the standard care group compared with 160 (25%) in the 
intervention group (risk ratio 0·96, 95% CI 0·79–1·16; p=0·68). 61 (8%) of 751 babies in the standard care group were 
large for gestational age compared with 71 (9%) of 761 in the intervention group (1·15, 0·83–1·59; p=0·40). Thus, the 
primary outcomes did not diﬀ er between groups, despite improvements in some maternal secondary outcomes in the 
intervention group, including reduced dietary glycaemic load, gestational weight gain, and maternal sum-of-skinfold 
thicknesses, and increased physical activity. Adverse events included neonatal death (two in the standard care group 
and three in the intervention group) and fetal death in utero (ten in the standard care group and six in the intervention 
group). No maternal deaths were reported. Incidence of miscarriage (2% in the standard care group vs 2% in the 
intervention group), major obstetric haemorrhage (1% vs 3%), and small-for-gestational-age infants (≤5th customised 
birthweight centile; 6% vs 5%) did not diﬀ er between groups.
Interpretation A behavioural intervention addressing diet and physical activity in women with obesity during pregnancy 
is not adequate to prevent gestational diabetes, or to reduce the incidence of large-for-gestational-age infants.
Funding National Institute for Health Research, Guys and St Thomas’ Charity, Chief Scientist Oﬃ  ce Scotland, 
Tommy’s Charity.
Copyright © Poston et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
In 2013, an estimated one in ﬁ ve women in the world aged 
20 years or older was obese (BMI ≥30 kg/m²).1 Obesity in 
women was most widespread in high-income countries, 
with a prevalence of 25% in the UK and 34% in the USA.1
Pregnant women with obesity are at risk of many 
complications, with insulin resistance and gestational 
diabetes being major concerns because they beget 
important adverse outcomes. These include stillbirth, 
large-for-gestational-age infants, and associated 
complications at birth.2 Children born to women with 
gestational diabetes could themselves be at risk of 
metabolic disease in later life.3
The increasing global problem of obesity in maternity 
care has led to national guideline recommendations for 
the development of interventions to improve pregnancy 
outcomes.4,5 This advice stimulated many clinical trials, 
predominantly of behavioural interventions addressing 
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diet and physical activity. However, most trials have been 
underpowered for clinical outcomes such as gestational 
diabetes, focusing instead on restriction of gestational 
weight gain.6 Nonetheless, systematic reviews of these 
mostly small trials suggest the potential for prevention of 
gestational diabetes in women with obesity by behaviour 
change interventions in pregnancy.7,8
Here, we report the results of the UK Pregnancies 
Better Eating and Activity Trial (UPBEAT), a randomised 
controlled trial of a complex behavioural intervention 
addressing diet and physical activity versus standard 
antenatal care. The behavioural intervention was 
designed to prevent maternal gestational diabetes and 
reduce the incidence of large-for-gestational-age infants. 
By contrast with interventions tested in many previous 
small-scale studies,6 the intervention was more intensive 
in design. Findings of a pilot study have shown feasibility, 
acceptability, and eﬃ  cacy of the intervention to change 
lifestyle behaviours.9
Methods
Study design
We did this multicentre, randomised controlled trial at 
antenatal clinics in eight inner-city NHS Trust Hospitals 
in the UK—London (three centres), Bradford, Glasgow, 
Manchester, Newcastle, and Sunderland. The detailed 
study design and protocol have been published elsewhere.10 
A ﬂ ow chart of the protocol is shown in the appendix (p 1). 
We did the study according to the UK’s National Institute 
for Health and Care Excellence (NICE) guidelines for 
diabetes in pregnancy, in which early pregnancy 
biochemistry screening for glucose intolerance and risk of 
gestational diabetes is not recommended.11 The NHS 
research ethics committee approved the study protocol for 
all centres (UK integrated research application system, 
reference 09/H0802/5). The trial steering committee 
approved the protocol and the analysis plan and provided 
oversight of all aspects of the trial, including safety.
Participants
We recruited women older than 16 years with a BMI of 
30 kg/m² or higher and a singleton pregnancy between 
15 weeks and 18 weeks plus 6 days of gestation. 
We excluded individuals if they were unwilling or unable 
to give informed consent; if they had underlying 
disorders, including a pre-pregnancy diagnosis of 
essential hypertension, diabetes, renal disease, systemic 
lupus erythematosus, antiphospholipid syndrome, sickle-
cell disease, thalassaemia, coeliac disease, thyroid disease, 
and current psychosis; or if they were currently being 
prescribed metformin. All participants provided written 
informed consent. For women who declined to participate, 
we recorded age, BMI, ethnic origin, socioeconomic 
status, and outcome data if permission was granted.
Randomisation and masking
We randomly allocated participants to either standard 
antenatal care or the behavioural intervention plus 
standard antenatal care. We used a computer-generated 
randomisation procedure via a password-protected 
website. Allocation to study groups was done by the 
centre’s UPBEAT trial midwife. We used minimisation, 
according to ethnic origin (black, white, Asian, other), 
parity (primiparous, multiparous), age (≤24, 25–29, 30–34, 
For the protocol see http://www.
kcl.ac.uk/lsm/research/divisions/
wh/clinical/open/UPBEAT-
protocol.pdf
Research in context
Evidence before this study
Obesity is a risk factor for complications in pregnancy, 
particularly gestational diabetes, large-for-gestational-age 
babies, and associated adverse outcomes. In a systematic 
review of 44 randomised controlled trials of behavioural 
interventions in pregnant women, irrespective of BMI, lifestyle 
interventions were shown to possibly improve clinical 
outcomes for both mother and baby. We and others have 
undertaken systematic reviews restricted to behavioural 
interventions in women with obesity, suggesting the potential 
for prevention of gestational diabetes. The contributing trials 
were mostly small scale and not powered for robust detection 
of diﬀ erences in clinical outcomes. In the LIMIT trial of more 
than 2000 overweight and obese women, no reduction in 
gestational diabetes was recorded in individuals who took part 
in a lifestyle intervention, although gestational diabetes was 
not the primary endpoint of the trial. 
Added value of this study
Our study compared a theory-based and intensive behavioural 
intervention with standard antenatal care for obese pregnant 
women from communities of ethnic diversity and high levels of 
socioeconomic deprivation. The intervention improved diet 
and physical activity, and modest reductions were noted in 
maternal weight gain and fat mass, but it had no eﬀ ect on the 
incidence of gestational diabetes or large-for-gestational-age 
infants. Use of an oral glucose tolerance test and diagnosis of 
gestational diabetes with the stringent IADPSG diagnostic 
criteria (also used by WHO) was associated with a lower than 
anticipated incidence of large-for-gestational-age infants in the 
trial population.
Interpretation
An intervention addressing diet and physical activity in 
high-risk women with obesity does not prevent gestational 
diabetes or reduce the incidence of large-for-gestational-age 
infants. We recommend a shift in research focus towards 
improved screening for and treatment of gestational 
diabetes, in addition to renewed eﬀ orts towards eﬀ ective 
public health measures that prevent obesity in women of 
reproductive age. 
For more on the randomisation 
website see http://medscinet.
com
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≥35 years), BMI (30·0–34·9, 35·0–39·9, ≥40 kg/m²), and 
centre. In view of the nature of the intervention, 
participants and staﬀ  were aware of allocations.
Procedures
Within 1 week of randomisation, women in the 
intervention group attended an individual interview at 
their trial centre with a health trainer (a person with skills 
in assisting behavioural change, but not necessarily a 
health professional) who received coaching in all aspects of 
the intervention and ongoing support throughout the 
study period.10 The intervention, which was informed by 
control theory and elements of social cognitive theory, 
consisted of eight further health trainer-led group or 
individual sessions of 1 h duration once a week for 
8 weeks.10 If a participant could not attend a session in 
person, the material was covered by telephone or email, 
providing ﬂ exibility in intervention delivery. Every session 
addressed approaches to achieving SMART goals (ie, 
speciﬁ c, measurable, achievable, relevant, time-speciﬁ c) 
and reviewed the previous week’s goals. Women assigned 
to the intervention received advice on: self-monitoring, 
identiﬁ cation, and problem-solving of barriers to behaviour 
change; enlisting social support; and providing oppor tu-
nities for social comparison. We encouraged participants 
to attend all sessions and provided them with a handbook 
in which information was included about the intervention 
and the theory behind it, with recommended foods and 
recipes, and suggestions for physical activity. We also gave 
the women a DVD of an exercise regimen that was safe for 
pregnancy, a pedometer, and a log book for recording their 
weekly SMART goals. The intention of the intervention 
was to improve glucose tolerance through dietary and 
physical activity behaviour change. With the dietary 
intervention we aimed to promote a healthy pattern of 
eating but not necessarily to restrict energy intake. 
We tailored recommendations to the woman’s habitual 
diet and cultural preference, and suggested exchanging 
carbohydrate-rich foods with a medium-to-high glycaemic 
index for those with a lower glycaemic index to reduce the 
glycaemic load, and restricting dietary intake of saturated 
fat. With respect to advice on physical activity, we focused 
on incremental increases in walking from a pedometer-
assessed baseline, tailored to pre-existing activities. The 
emphasis of the exercise intervention was on walking at a 
moderate intensity, with additional options included, 
particularly for women already engaging in some physical 
activity. Further details are available in the protocol.10 
Women in the intervention group continued with their 
routine antenatal care appointments.
Women who were allocated to the standard antenatal 
care group continued to attend routine antenatal 
appointments at their trial centre, in accordance with 
local practice. Typically, women would attend nine 
appointments. Recommendations of UK guidelines are 
for women with obesity to be advised, at ﬁ rst contact with 
a health professional, and at no other time, about a 
healthy diet and the beneﬁ ts of physical activity.5,11 We did 
not provide any additional information, including any 
details of the nature of the intervention. 
For diagnosis of gestational diabetes, we gave all 
participants an oral glucose tolerance test (75 g load) 
between 27 weeks and 28 weeks plus 6 days of gestation. 
We used diagnostic criteria recommended by the 
International Association of Diabetes and Pregnancy 
Study Groups (IADPSG)—ie, fasting venous glucose of 
5·1 mmol/L or higher, 1 h venous glucose of 10·0 mmol/L 
or higher, 2 h venous glucose of 8·5 mmol/L or higher, or 
a combination of these.12 We used these criteria not only 
because of their increasing adoption globally (and by 
WHO) but also because of diﬀ erences in routine diagnostic 
criteria used by trial centres. We referred women who were 
diagnosed with gestational diabetes for antenatal diabetic 
services, according to local practice at every centre.
To assess the eﬃ  cacy of the behavioural intervention, 
we gathered maternal dietary data and physical activity 
scores, calculated gestational weight gain, and took 
maternal anthropometric measurements. We used 
standard laboratory methods to measure biochemical 
outcomes between 27 weeks and 28 weeks plus 6 days of 
gestation.
We used a food frequency questionnaire10,13 to assess the 
diet of participants for the month before randomisation 
and for the month before the study visit at between 
27 weeks and 28 weeks plus 6 days of gestation. We adapted 
this questionnaire from one used in the UK arm of the 
European Prospective Investigation into Cancer Study.13 
We used WISP 3.0 (Tinuviel Software, Llanfechell, 
Anglesey, UK) to calculate nutritional composition and 
glycaemic load per 100 g of food and beverage items. 
We excluded from the analysis data for participants who 
we estimated were under-reporting (≤4·5 MJ/day) and 
over-reporting (≥20 MJ/day).14
We measured physical activity at randomisation and 
at the study visit between 27 weeks and 28 weeks plus 
6 days of gestation. We used the International Physical 
Activity Questionnaire (IPAQ) and summarised data 
according to established methods.10 We calculated 
physical activity (min/week) as metabolic equivalents 
(METs)—ie, the ratio of energy expenditure for an activity 
to energy expenditure at rest—with the formula 
8·0 × vigorous activity + 4·0 × moderate activity + 3·3 × light 
activity (walking).
At delivery of the infant, we measured and weighed the 
baby. We calculated customised birthweight centiles with 
Gestation Related Optimal Weight (GROW) software, 
version 6.7.5.1 (Gestation Network, Perinatal Institute, 
Birmingham, UK).
Outcomes
The primary maternal outcome was gestational diabetes. 
Prespeciﬁ ed secondary outcomes included dietary 
measures, physical activity scores, gestational weight gain, 
maternal anthropometric measurements (mid-arm and 
For more on GROW software 
see http://www.gestation.net
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thigh circumference and subscapular, triceps, biceps, and 
suprailiac skinfold thicknesses), and biochemical 
outcomes (maternal fasting plasma glucose, fasting 
plasma insulin, insulin resistance [calculated by 
homoeostatic model assessment, HOMA2-IR],15 fasting 
triglycerides, LDL cholesterol, HDL cholesterol, and VLDL 
cholesterol). We prespeciﬁ ed several other secondary 
clinical maternal outcomes: pre-eclampsia (deﬁ ned as 
systolic blood pressure ≥140 mm Hg, diastolic blood 
pressure ≥90 mm Hg, or both, on at least two occasions 
4 h apart, with proteinuria ≥300 mg/24 h or spot urine 
protein:creatinine ratio ≥30 mg/mmol creatinine, or urine 
dipstick protein ≥2+); severe pre-eclampsia (deﬁ ned as 
systolic blood pressure ≥170 mm Hg, diastolic blood 
pressure ≥110 mm Hg, or both, with proteinuria 
≥500 mg/24 h or spot urine protein:creatinine ratio 
≥50 mg/mmol creatinine, or urine dipstick protein ≥3+); 
mode of delivery (elective or emergency caesarean section, 
vaginal delivery, or operative vaginal delivery); induction 
of labour; blood loss at delivery (>1000 mL or >2000 mL); 
inpatient nights (antenatal and postnatal); referral to 
diabetic antenatal service after oral glucose tolerance test; 
and a requirement for insulin or metformin during 
pregnancy. Prespeciﬁ ed maternal secondary outcomes not 
reported here are listed in the appendix (p 2).
The primary neonatal outcome was delivery of a large-
for-gestational-age infant, which we deﬁ ned as the 90th or 
higher customised birthweight centile for gestational age, 
adjusting for maternal height and weight, ethnic origin, 
parity, and sex of the baby. We prespeciﬁ ed several 
secondary neonatal outcomes: gestational age at delivery; 
delivery at less than 37 weeks and less than 34 weeks; 
birthweight; birthweight 4·0 kg or heavier, 2·5 kg or 
lighter, or 1·5 kg or lighter; customised birthweight centile 
(≥95th, ≤10th, and ≤5th); neonatal death; days in special 
care baby unit; total inpatient days; discharge home on 
oxygen; conﬁ rmed infection; retinopathy of prematurity; 
neonatal hypoglycaemia; intraventricular haemorrhage; 
need for mechanical ventilation and duration; necrotising 
enterocolitis; pulmonary haemorrhage, skinfold 
thicknesses and circumferences; and birthweight centiles 
as population centiles (≥90th, ≥95th, ≤10th, and ≤5th). 
Prespeciﬁ ed neonatal secondary outcomes not reported 
here are listed in the appendix (p 2).
Figure: Trial proﬁ le 
651 completed oral glucose tolerance test 
(618 at predefined timepoint; 33 within 
6 days)
120 without oral glucose tolerance test results
 14 test outside dates
 23 did not attend
 69 declined further visits
 14 loss of pregnancy
629 completed oral glucose tolerance test 
(589 at predefined timepoint; 40 within 
6 days)
 154 without oral glucose tolerance test results
 11 test outside dates
 19 did not attend
 110 declined further visits
 14 loss of pregnancy
757 infants with known birthweight
 14 without birthweight
 2 lost to follow-up
 3 withdrew permission to use data
 2 miscarriages
 4 fetal deaths in utero (unweighed)
 3 terminations
765 infants with known birthweight
 18 without birthweight
 6 lost to follow-up
 3 withdrew permission to use data
 6 miscarriages
 2 fetal deaths in utero (unweighed)
 1 termination
651 primary maternal outcomes
751 primary neonatal outcomes
 6 fetal deaths in utero excluded
629 primary maternal outcomes
761 primary neonatal outcomes
 4 fetal deaths in utero excluded
772 allocated standard antenatal care 783 allocated intervention
1 excluded after enrolment 
   on another trial
1555 randomised
8820 women assessed for inclusion
7265 excluded
 438 not eligible when reassessed
 6704 declined to participate
 123 termination or miscarriage
3711 agreed to use of routine data
Standard care 
(n=772)
Intervention 
(n=783)
Age (years) 30·4 (5·6) 30·5 (5·5)
BMI (kg/m2) 36·3 (4·6) 36·3 (5·0)
Ethnic origin .. ..
White 483 (63%) 490 (63%)
Black 200 (26%) 202 (26%)
Asian 48 (6%) 47 (6%)
Other 41 (5%) 44 (6%)
Parity .. ..
Primiparous 338 (44%) 336 (43%)
Multiparous 434 (56%) 447 (57%)
Current smoker 60 (8%) 48 (6%)
Previous history of gestational 
diabetes (multiparous only)
13/434 (3%) 19/447 (4%)
Family history of type 2 diabetes 181/767 (24%) 194/772 (25%)
Family history of gestational 
diabetes
20/742 (3%) 38/760 (5%)
Index of multiple deprivation* .. ..
1 (least deprived) 36/771 (5%) 29/778 (4%)
2 44/771 (6%) 59/778 (8%)
3 84/771 (11%) 93/778 (12%)
4 289/771 (37%) 245/778 (31%)
5 (most deprived) 318/771 (41%) 352/778 (45%)
Data are mean (SD) or number of women/total (%). *Scores were calculated for the 
region of residence, by ﬁ fths of the population. UK-wide scores were developed 
from English and Scottish data relating to employment and income domains.
Table 1: Baseline characteristics of women 
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Adverse events other than those prespeciﬁ ed as 
secondary outcomes included miscarriage, late 
termination of pregnancy, maternal accident, placental 
abruption, antenatal and postnatal sepsis, iatrogenic 
premature birth, intrauterine complications (fetal 
cardiac, renal, respiratory, and neurological), fetal death 
in utero, unspeciﬁ ed neonatal complications at birth, 
and conﬁ rmed neonatal sepsis.
Statistical analysis
We calculated that a sample size of 1546 women (allowing 
for 20% dropout) would provide at least 80% power to 
detect a clinically important 25% reduction in the 
incidence of gestational diabetes, from 30% (observed in 
the pilot study of 183 women)9 to 23%. From a review of 
published population birthweight centiles in obese UK 
women,16 1546 infants provided 80% power to detect a 
30% relative risk reduction for large-for-gestational-age 
infants (17·2% to 12·0%).
Our analysis was by intention to treat. We expressed 
treatment eﬀ ects for binary endpoints as risk ratios 
(relative risk) with 95% CIs, using binomial regression 
and adjusting for maternal BMI, ethnic origin, and 
parity (ie, minimisation variables for intervention 
allocation). We calculated risk diﬀ erences and did 
signiﬁ cance tests for both primary endpoints. For 
continuous measurements, we used linear regression 
with robust SEs, adjusting for baseline data or the 
variables used for minimisation. For physical activity 
data, we did median regression. For biochemical data, 
we did log transformations for normality, as appropriate. 
To check for the potential of a variable response to the 
intervention, we did subgroup analyses with interaction 
tests for BMI, ethnic origin, socioeconomic status, 
parity, and smoking. Moreover, to ascertain whether 
attendance at intervention sessions aﬀ ected outcome, 
we did further interaction tests.
For the main analysis, we followed the missing-at-
random assumption. Predictors of missingness, which 
we included to ensure an unbiased measure of treatment 
eﬀ ect, were maternal BMI, ethnic origin, and parity. 
To test the possibility of undetectable bias attributable to 
missing data, we did a series of analyses under diﬀ erent 
missing-not-at-random assumptions for the primary 
Standard care Intervention Eﬀ ect of intervention p
Risk ratio (95% CI) Mean diﬀ erence (95% CI)
Gestational diabetes 172/651 (26%) 160/629 (25%) 0·96 (0·79–1·16) –1·2% (–5·8 to 3·8)* 0·68
Fasting blood glucose (mmol/L) 4·71 (0·6), n=651 4·68 (0·6), n=629 .. –0·02 (–0·09 to 0·04) 0·49
1 h blood glucose (mmol/L) 8·02 (2·1), n=605 7·91 (2·1), n=584 .. –0·10 (–0·33 to 0·14) 0·43
2 h blood glucose (mmol/L) 5·94 (1·5), n=650 5·96 (1·5), n=628 .. 0·02 (–0·15 to 0·19) 0·81
Treatment of gestational 
diabetes†
.. .. .. .. ..
Dietary advice 69/146 (47%) 62/127 (49%) 1·03 (0·81–1·32) .. 0·80
Metformin 35/146 (24%) 34/127 (27%) 1·12 (0·74–1·68) .. 0·60
Metformin and insulin 16/146 (11%) 14/127 (11%) 1·01 (0·51–1·98) .. 0·99
Insulin 26/146 (18%) 17/127 (13%) 0·75 (0·43–1·32) .. 0·32
All pre-eclampsia 27/752 (4%) 27/753 (4%) 1·00 (0·59–1·69) .. >0·99
Severe pre-eclampsia 10/752 (1%) 6/753 (1%) 1·64 (0·60–4·49) .. 0·33
Labour and delivery .. .. .. .. ..
Induction of labour 275/757 (36%) 251/765 (33%) 0·90 (0·79–1·04) .. 0·15
Unassisted vaginal delivery 399/757 (52%) 400/765 (52%) 0·99 (0·90–1·09) .. 0·87
Operative vaginal delivery 84/757 (11%) 94/765 (12%) 1·11 (0·84–1·46) .. 0·47
Caesarean section 274/757 (36%) 271/765 (35%) 0·98 (0·86–1·12) .. 0·75
Elective caesarean section 136/757 (18%) 160/765 (21%) 1·16 (0·95–1·43) .. 0·15
Emergency caesarean section 138/757 (18%) 111/765 (14%) 0·80 (0·63–1·00) .. 0·051
Post partum haemorrhage (mL) .. .. .. .. ..
≥1000 91/747 (12%) 109/755 (14%) 1·19 (0·91–1·54) .. 0·20
≥2000 10/747 (1%) 20/755 (3%) 1·98 (0·93–4·20) .. 0·075
Inpatient nights (n) 2·3 (1·8), n=691 2·4 (1·9), n=691 .. 0·14 (–0·06 to 0·34) 0·16
Antenatal 2·9 (2·5), n=65 2·9 (3·5), n=74 .. –0·02 (–0·98 to 0·95) 0·98
Postnatal 2·2 (1·7), n=685 2·3 (1·6), n=684 .. 0·08 (–0·09 to 0·25) 0·37
Gestational weight gain (kg)‡ .. .. .. .. ..
Total 7·76 (4·6), n=567 7·19 (4·6), n=526 .. –0·55(–1·08 to –0·02) 0·041
Before pregnancy to 
27–28 weeks + 6 days
5·40 (3·3), n=664 4·97 (2·9), n=637 .. –0·42(–0·75 to –0·09) 0·013
(Table 2 continues on next page)
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maternal and neonatal endpoints, with the Stata 
command rctmiss. We tested the assumptions that the 
odds of disease in participants with missing data were 
variously half or double that for women with complete 
data, in both study groups or in one group only. We did 
all analyses with Stata version 13.1.
This trial is registered with Current Controlled Trials, 
ISCRTN89971375.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
From March 31, 2009, to June 2, 2014, 8820 pregnant 
women with a BMI of 30 kg/m² or higher were assessed 
for inclusion. Of 8259 eligible individuals, 1555 (19%) 
gave informed consent to participate and were randomly 
allocated to either standard antenatal care (n=772) or the 
behavioural intervention (n=783; ﬁ gure). The mean BMI 
of participants was 36·3 kg/m² (SD 4·8); three-quarters 
of women were in the two highest quintiles of the index 
of multiple deprivation (table 1). Compared with 
3711 individuals who declined to participate but agreed to 
use of routine data, participants were on average 
10 months older and had a BMI that was 0·7 kg/m² 
higher (appendix p 3).
On average, women who were assigned the intervention 
attended seven (SD 3) of eight health trainer-led sessions, 
including four in person, and a further three by telephone 
or email. For sessions attended in person, 30% of women 
attended only one session, and 46% attended fewer than 
four. For sessions delivered by any method, 10% of women 
received only one session and 17% had fewer than four.
629 (80%) women in the intervention group and 
651 (84%) in the standard care group had an oral glucose 
tolerance test and could be assessed for the primary 
maternal outcome. Demographic variables were similar 
between groups for women with primary outcome data 
(appendix p 4). The main reason for missing outcome 
data was that participants declined to attend further study 
Standard care Intervention Eﬀ ect of intervention p
Risk ratio (95% CI) Mean diﬀ erence (95% CI)
(Continued from previous page)
Mid-arm circumference (cm) .. .. .. .. ..
15–18 weeks + 6 days 36·8 (4·0), n=766 36·7 (4·1), n=775 .. .. ..
27–28 weeks + 6 days 36·9 (4·2), n=663 36·6 (4·0), n=634 .. –0·19 (–0·39 to 0·01) 0·063
34–36 weeks + 0 days 36·6 (4·1), n=567 36·5 (3·9), n=526 .. –0·10 (–0·32 to 0·13) 0·40
Thigh circumference (cm) .. .. .. .. ..
15–18 weeks + 6 days 68·6 (6·5), n=766 68·6 (6·8), n=775 .. .. ..
27–28 weeks + 6 days 69·2 (6·8), n=662 68·9 (6·6), n=635 .. –0·10 (–0·54 to 0·33) 0·64
34–36 weeks + 0 days 69·3 (6·7), n=566 68·9 (7·0), n=526 .. –0·48 (–1·01 to 0·05) 0·078
Sum of skinfold thicknesses 
(mm)§
.. .. .. .. ..
15–18 weeks + 6 days 123 (27), n=763 123 (29), n=771 .. .. ..
27–28 weeks + 6 days 127 (26), n=661 124 (27), n=632 .. –2·3 (–4·3 to –0·3) 0·022
34–36 weeks + 0 days 125 (27), n=561 122 (26), n=520 .. –3·2 (–5·6 to –0·8) 0·0081
Plasma fasting insulin (mU/L) 23·2 (2·4), n=510 22·5 (2·3), n=480 .. 0·97 (0·87 to 1·08)¶ 0·57
HOMA2-IR (units) 3·04 (2·1), n=496 2·99 (2·1), n=471 .. 0·98 (0·89 to 1·07)¶ 0·60
Plasma triglycerides (mmol/L) .. .. .. .. ..
27–28 weeks + 6 days 1·98 (1·41), n=505 1·92 (1·40), n=478 .. 0·99 (0·96 to 1·02)¶ 0·39
Plasma LDL cholesterol (mmol/L) .. .. .. .. ..
27–28 weeks + 6 days 3·66 (1·31), n=509 3·66 (1·35), n=479 .. 1·01 (0·99 to 1·04)¶ 0·27
Plasma HDL cholesterol (mmol/L) .. .. .. .. ..
27–28 weeks + 6 days 1·80 (1·29), n=509 1·80 (1·28), n=479 .. 1·00 (0·98 to 1·02)¶ 0·93
Plasma VLDL cholesterol 
(mmol/L)||
.. .. .. .. ..
27–28 weeks + 6 days 0·40 (1·41), n=505 0·38 (1·40), n=478 .. 0·99 (0·96 to 1·02)¶ 0·39
Data are number of women/total (%) or mean (SD), number of women. HOMA2-IR=homoeostatic model assessment. *For the primary maternal outcome, the risk diﬀ erence 
(95% CI) is presented. †Treatment was recorded in women with gestational diabetes diagnosed according to predeﬁ ned study criteria. ‡Gestational weight gain calculated using 
estimated weight before pregnancy. §Calculated by addition of biceps, triceps, suprailiac, and subscapular skinfold thicknesses. ¶For biochemistry data, the ratio of means (95% CI) 
is presented. ||Calculated by Friedewald formula (triglycerides/5). 
Table 2: Maternal outcomes 
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visits (ﬁ gure). 129 (16%) women in the intervention group 
failed to complete the oral glucose tolerance test compared 
with 92 (12%) in the standard care group (p=0·02).
The incidence of gestational diabetes was similar 
between groups (table 2). Of women who had an oral 
glucose tolerance test, ten women in the intervention 
group and eight in the standard care group had their test 
done outside the predeﬁ ned period. A sensitivity analysis 
excluding all data obtained outside this period gave similar 
results to the main analysis (intervention 150 [25%] of 589 
vs standard care 164 [27%] of 618; risk ratio 0·96, 95% CI 
0·79–1·16; p=0·67).
Compared with women assigned standard antenatal 
care, glycaemic index was reduced in participants 
assigned the intervention, as was mean intake of total 
energy, carbohydrate, saturated fat, and total fat; protein 
and ﬁ bre intake was increased (table 3). Physical activity 
was higher at 27–28 weeks plus 6 days of gestation in 
women in the intervention group versus the standard 
care group, which was attributable to more time spent 
walking (table 3).
Women in the intervention group had less gestational 
weight gain than did those in the standard care group at 
the time of the oral glucose tolerance test, and over the 
entire pregnancy (table 2). The sum of maternal skinfold 
thicknesses was also lower with the intervention at 
27–28 weeks plus 6 days of gestation and at 34–36 weeks 
of gestation (table 2). Mode of delivery, post partum 
haemorrhage, or treatment of gestational diabetes did not 
diﬀ er between groups; likewise, no diﬀ erences were 
noted between groups in fasting glucose, fasting insulin, 
or HOMA2-IR, or in any other biochemical variables 
measured at 27–28 weeks plus 6 days of gestation (table 2).
761 infants born to women allocated the intervention 
and 751 infants born to mothers in the standard care 
group had a known birthweight and could be assessed 
for the primary neonatal outcome (≥90th customised 
birthweight centile; table 4). The incidence of large-for-
gestational-age infants did not diﬀ er between groups. 
Similar results were recorded in a sensitivity analysis 
allowing for possible selective bias in missing data (odds 
ratio 0·95, 95% CI 0·72–1·25, assuming a halving of the 
odds of large-for-gestational-age infants in the inter-
vention group with missing data).
By population birthweight centiles (secondary outcome), 
12% of infants were in the 90th centile or higher, and 
there was no diﬀ erence between groups. Similarly, other 
neonatal secondary outcomes did not diﬀ er between 
groups, with the exception of neonatal hypoglycaemia, 
which was increased in the intervention group (table 4). 
As neonatal hypoglycaemia is treatable, it is not judged a 
severe adverse event. Neonatal anthropometric measures 
were evaluated in a subgroup of infants and did not diﬀ er 
between groups (appendix p 5).
Table 5 shows adverse events that were not prespeciﬁ ed 
as secondary outcomes. Adverse events did not diﬀ er 
between intervention and standard care groups.
Interaction tests for prespeciﬁ ed maternal demographic 
variables (BMI, ethnic origin, socioeconomic status, parity, 
and smoking) did not diﬀ er between standard care and 
intervention groups for the primary maternal or neonatal 
Standard care Intervention Mean diﬀ erence 
(95% CI)
p
Nutrition
Total energy (MJ/day)
15–18 weeks + 6 days 7·8 (2·6) 7·6 (2·5) .. ..
27–28 weeks + 6 days 7·5 (2·3) 6·8 (1·9) –0·70 (–0·96 to –0·45) <0·0001
Glycaemic index (0–100)
15–18 weeks + 6 days 56·9 (4·1) 56·8 (3·9) .. ..
27–28 weeks + 6 days 57·0 (3·9) 54·3 (3·9) –2·6 (–3·0 to –2·1) <0·0001
Glycaemic load per day
15–18 weeks + 6 days 141 (56) 135 (51) .. ..
27–28 weeks + 6 days 133 (47) 112 (38) –21 (–26 to –16) <0·0001
Carbohydrate (% energy)
15–18 weeks + 6 days 49·4 (7·4) 49·0 (7·4) .. ..
27–28 weeks + 6 days 48·6 (6·6) 47·2 (7·2) –1·4 (–2·2 to –0·58) 0·0011
Protein (% energy)
15–18 weeks + 6 days 19·7 (4·4) 20·1 (4·5) .. ..
27–28 weeks + 6 days 20·1 (4·0) 22·3 (4·6) 2·05 (1·5 to 2·5) <0·0001
Total fat (% energy)
15–18 weeks + 6 days 31·0 (5·5) 31·0 (5·3) .. ..
27–28 weeks + 6 days 31·5 (5·1) 30·5 (5·2) –0·88 (–1·49 to –0·26) 0·0011
Saturated fat (g/day)
15–18 weeks + 6 days 26·5 (11·5) 25·4 (11·0) .. ..
27–28 weeks + 6 days 26·4 (10·9) 22·0 (8·3) –4·3 (–5·4 to –3·1) <0·0001
Saturated fat (% energy)
15–18 weeks + 6 days 12·7 (3·0) 12·5 (2·9) .. ..
27–28 weeks + 6 days 13·1 (3·0) 12·1 (2·8) –0·85 (–1·2 to –0·51) <0·0001
Fibre (g/day)
15–18 weeks + 6 days 13·6 (6·0) 13·1 (5·3) .. ..
27–28 weeks + 6 days 12·6 (5·3) 13·4 (5·3) 0·83 (0·17 to 1·48) 0·013
Physical activity
MET (min/week)
15–18 weeks + 6 days 1386 (660–3052) 1386 (594–2982) .. ..
27–28 weeks + 6 days 1386 (639–3363) 1836 (792–4158) 295 (105 to 485)* 0·0015
Moderate or vigorous 
activity (min/week)
15–18 weeks + 6 days 0 (0–180) 0 (0–180) .. ..
27–28 weeks + 6 days 0 (0–240) 30 (0–240) 0 (–18 to 18)* >0·99
Walking (min/week)
15–18 weeks + 6 days 280 (140–600) 280 (140–540) .. ..
27–28 weeks + 6 days 300 (132–630) 420 (180–840) 77 (28 to 126)* 0·0018
Data are mean (SD) or median (IQR). Women with reported total energy ≤4·5 MJ/day or ≥20 MJ/day at 15–18 weeks + 6 days 
of gestation were excluded from analyses of diet. Thus, in the standard care group, 571 women were assessed at 
15–18 weeks + 6 days of gestation and 511 were assessed at 27–28 weeks + 6 days of gestation; corresponding ﬁ gures in the 
intervention group were 574 and 435.  Dietary intervention estimates were calculated by multiple regression and adjusted 
for pretrial values. For analyses of physical activity, in the standard care group, 678 women were included at 
15–18 weeks + 6 days of gestation and 588 were assessed at 27–28 weeks + 6 days of gestation; in the intervention group, 
683 and 559 women, respectively, were analysed. Physical activity estimates were calculated by bootstrapped 
(1000 replications) median regression, adjusting for pretrial values. MET is deﬁ ned as the energy expenditure ratio of activity 
to rest; one MET is roughly equal to an individual’s resting energy expenditure. MET, vigorous activity, moderate or vigorous 
activity, and walking were not prespeciﬁ ed endpoints. MET=metabolic equivalent of task. *Median diﬀ erence (95% CI).
Table 3: Maternal nutritional and physical activity outcomes, by period of gestation 
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outcomes (appendix p 6). Furthermore, no diﬀ erences 
were recorded in maternal and neonatal primary outcomes 
with respect to whether the intervention had been delivered 
mainly in person or by telephone or email (maternal 
p=0·39; neonatal p=0·54), nor for women who attended 
more versus less than half the health trainer-led sessions 
(maternal p=0·56; neonatal p=0·59).
Discussion
Our ﬁ ndings suggest that a complex intervention 
addressing diet and physical activity in pregnant women 
with obesity is eﬀ ective at improving diet quality and 
physical activity, reducing gestational weight gain, and 
decreasing surrogate measures of maternal body fatness. 
However, the intervention does not prevent development 
of gestational diabetes nor change the incidence of large-
for-gestational-age infants in this population. Neither 
was evidence noted of a beneﬁ t on other pregnancy 
outcomes, including pre-eclampsia, which is associated 
with raised BMI.
By contrast with previous systematic reviews and meta-
analyses of studies on a smaller scale to ours,7,8 our null 
ﬁ nding extends some observations. In particular, in 
two Danish studies of lifestyle interventions,17,18 more than 
350 obese pregnant women in each study were screened 
with an oral glucose tolerance test. Although analysis was 
not by intention-to-treat, a reduction in the primary 
outcome of gestational weight gain of around 1·5 kg was 
Standard care Intervention Eﬀ ect of intervention p
Risk ratio (95% CI) Mean diﬀ erence 
(95% CI)
Large for gestational age (customised birthweight 
centiles)
.. .. .. .. ..
≥90th 61/751 (8%) 71/761 (9%) 1·15 (0·83–1·59) 1·2% (–1·6 to 4·1)* 0·40
≥95th 32/751 (4%) 39/761 (5%) 1·20 (0·76–1·90) .. 0·43
≤10th 76/751 (10%) 95/761 (13%) 1·24 (0·93–1·64) .. 0·15
≤5th 43/751 (6%) 36/761 (5%) 0·83 (0·54–1·27) .. 0·39
Population birthweight centiles .. .. .. .. ..
≥90th 83/750 (11%) 96/761 (13%) 1·14 (0·87–1·50) .. 0·35
≥95th 42/750 (6%) 51/761 (7%) 1·20 (0·81–1·78) .. 0·37
≤10th 38/750 (5%) 53/761 (7%) 1·38 (0·92–2·06) .. 0·12
≤5th 19/750 (3%) 22/761 (3%) 1·14 (0·62–2·09) .. 0·67
Birthweight (kg) 3450 (580), n=751 3420 (580), n=761 .. –27 (–85 to 31) 0·37
≥4 105/751 (14%) 105/761 (14%) 0·99 (0·77–1·27) .. 0·93
≤2·5 36/751 (5%) 31/761 (4%) 0·85 (0·53–1·36) .. 0·50
≤1·5 9/751 (1%) 7/761 (1%) 0·77 (0·29–2·05) .. 0·60
Gestational age at birth (weeks) 39·5 (2·4), n=751 39·5 (2·0), n=761 .. 0·02 (–0·2 to 0·2) 0·89
Delivery ≤37 weeks 48/751 (6%) 45/761 (7%) 0·93 (0·62–1·37) .. 0·70
Delivery ≤34 weeks 16/751 (2%) 15/761 (2%) 0·93 (0·46–1·86) .. 0·83
Hospital admission .. .. .. .. ..
Admission to neonatal unit 57/751 (8%) 65/761 (9%) 1·13 (0·80–1·58) .. 0·49
Time spent in neonatal unit, if admitted (days) 16·8 (30·2), n=52 11·6 (23·5), n=61 .. –0·26 (–9·65 to 9·13) 0·96
Time spent in hospital after birth, if admitted 
(days)
3·0 (9·0), n=733 2·8 (7·3), n=743 .. –0·06 (–0·86 to 0·74) 0·88
Neonatal death 2/771 (<1%) 3/783 (<1%) 0·98 (0·14–6·97) .. 0·99
Intraventricular haemorrhage, grade 3–4 2/751 (<1%) 0/760 .. .. ..
Retinopathy of prematurity 1/751 (<1%) 1/760 (<1%) 0·99 (0·06–15·70) .. 0·99
Discharged home on oxygen 4/751 (1%) 2/760 (<1%) 0·49 (0·09–2·69) .. 0·41
Neonatal hypoglycaemia 12/751 (2%) 27/760 (4%) 2·22 (1·13–4·36) .. 0·020
Conﬁ rmed infection 14/751 (2%) 7/760 (1%) 0·49 (0·20–1·22) .. 0·13
Congenital abnormalities 6/751 (1%) 5/760 (1%) 0·82 (0·25–2·69) .. 0·75
Mechanical ventilation 21/751 (3%) 19/760 (3%) 0·89 (0·48–1·65) .. 0·72
Duration of mechanical ventilation (h) 500 (885), n=20 330 (573), n=16 .. –170 (–667 to 327) 0·49
Necrotising enterocolitis 2/751 (<1%) 0/760 .. .. ..
Pulmonary haemorrhage 2/751 (<1%) 1/760 (<1%) 0·49 (0·04–5·43) .. 0·56
Data are number of children/total (%) or mean (SD), number of children. Population centiles were calculated with WHO centiles. *For the primary neonatal outcome, the risk 
diﬀ erence (95% CI) is presented.
Table 4: Neonatal outcomes 
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recorded in both studies, but gestational diabetes was not 
decreased. In the Australian LIMIT randomised controlled 
trial in 2212 overweight and obese pregnant women,19 a 
lifestyle intervention less intense than ours (in terms of 
frequency and personal contact) had no eﬀ ect on 
gestational diabetes (a secondary outcome). Furthermore, 
no diﬀ erence was noted in the proportion of large-for-
gestational-age infants (the primary outcome) or in 
gestational weight gain, but the proportion of babies 4 kg 
or heavier at birth was lower in the intervention group.19 
The inference from systematic reviews that pregnancy 
lifestyle interventions might be an eﬀ ective means to 
prevent gestational diabetes in women with obesity seems 
to have been biased by small-scale studies and 
methodological limitations.6,7
On average, seven of the eight intervention sessions 
were attended by women assigned to the intervention, 
whether in person or by telephone or email. There was 
no indication that failure of adherence, mode of session 
delivery, ethnic origin, or socioeconomic status of the 
women aﬀ ected the primary outcomes. Further planned 
analyses will ascertain whether coverage of sessions 
aﬀ ected speciﬁ c elements of dietary and physical activity 
behavioural change. Measurement of several biomarkers 
of glucose intolerance and insulin resistance, as well as 
the metabolome, at study entry and after the intervention 
will also establish whether early risk stratiﬁ cation can 
identify a subgroup of women in whom the intervention 
could show clinical beneﬁ t.
Our study was set in UK inner-city settings of ethnic 
diversity and high socioeconomic deprivation. Black 
women were the predominant minority ethnic subgroup 
(26%); individuals of this ethnic origin have a high risk of 
obesity in pregnancy in the UK,20 which, as elsewhere, is 
strongly related to socioeconomic deprivation. Similar to 
previous studies,17–19 large numbers of women had to be 
approached to meet our recruitment target, and the drop-
out rate in our study for oral glucose tolerance testing was 
similar to previous studies.17,18 The reluctance of pregnant 
women with obesity to take part in a complex behavioural 
intervention suggests that lifestyle interventions can 
improve healthy behaviours, but only in a subgroup of 
motivated individuals. Likewise, the 5% higher proportion 
of women who dropped out of the study from the 
intervention group than the standard care group, although 
a limitation, was not unexpected. Despite small numerical 
diﬀ erences, participants were similar to individuals who 
declined participation with respect to demographic 
characteristics, suggesting generalisability of outcomes to 
populations of this demographic complexity.
The self-reported reduction in glycaemic load in the 
intervention group was larger than that noted in previous 
similar pregnancy intervention studies,21,22 a potential 
reﬂ ection of the intensity of our intervention, which 
included motivational interviewing every week for 
8 weeks, goal setting, and behavioural self-monitoring.23 
Together with reduced intake of saturated fat and total 
energy in the intervention group, these outcomes could 
be the reasons for the modest lowering of gestational 
weight gain and measures of fat mass noted in our study. 
Although we acknowledge the limitations of dietary 
assessment by self-report, the size of the improvement 
was similar to that recorded in the pilot trial,9 in which a 
more rigorous assessment method was used. Thus, 
we conclude that the behavioural intervention increases 
healthy dietary behaviours, but that the modest size of 
the eﬀ ect is inadequate to reduce the risk of gestational 
diabetes or improve insulin sensitivity in women who are 
obese at the time of conception.
The incremental rise in physical activity achieved with 
the intervention was also inadequate to improve glucose 
tolerance. A minimum of 16 MET h/week of physical 
activity has been suggested to be needed to reduce the 
risk of gestational diabetes,24 which equates to 41 min/day 
of walking; this amount is well above the 12–13 min 
increase (or <1 mile) reported by women in our study, 
which was similar to the increase in physical activity 
reported in the LIMIT trial intervention group.22 Again, 
we are aware of the limitations in accuracy of self-report; 
indeed, in the pilot trial, physical activity was assessed by 
accelerometry, and no increase in exercise levels was 
reported in the intervention group compared with 
women in the standard care group.9 However, this 
method of objective assessment is recognised to be 
ineﬀ ective at measuring low-intensity activity that, as we 
report here, was increased by self-report.
Although not the primary maternal outcome of this 
study, the 0·55 kg lower gestational weight gain in the 
intervention group compared with the standard care 
group adds to growing evidence from other studies that a 
substantial reduction in gestational weight gain is 
unlikely to be achievable in women with obesity through 
interventions adressing diet, physical activity, or both.17,18 
The reduction achieved was less than that reported in a 
meta-analysis of previous studies (–2·41 kg),6 which 
Standard 
care 
(n=772)
Intervention 
(n=783)
p*
All miscarriage 14 18 0·50
Late termination of pregnancy 3 1 ..
Maternal accident 1 0 ..
Placental abruption 0 1 ..
Maternal antenatal sepsis 1 0 ..
Maternal postnatal sepsis 1 0 ..
Iatrogenic preterm birth 2 2 ..
Intrauterine complications (cardiac, neurological, renal, respiratory) 2 3 ..
Fetal death in utero 10 6 0·30
Unspeciﬁ ed neonatal complications at birth 2 1 ..
Neonatal sepsis 1 0 ..
*p values were only calculated if data were suﬃ  cient. 
Table 5: Adverse events not prespeciﬁ ed as secondary outcomes
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could reﬂ ect our rigorous trial method (ie, intention-to-
treat analysis), the high mean BMI, ethnic diversity, and 
low socioeconomic status of the UPBEAT participants, or 
that gestational weight gain was not the main focus of 
this study.
Ongoing follow-up of mothers and their children in the 
UPBEAT study will ascertain whether the changes 
recorded in diet, physical activity, and maternal 
anthropometric measures are sustained or extended and 
can beneﬁ t maternal and child health in the longer term. 
Although gestational diabetes was not prevented, the 
behavioural intervention has the potential to reduce the 
risk of obesity and adverse metabolic risk in the child, 
because excessive gestational weight gain, high maternal 
fat mass, and increased glycaemic load are all associated 
independently with greater adiposity in the oﬀ spring, 
potentially through epigenetic pathways.3,25,26
We had anticipated that 17% of babies in our study would 
be in the 90th centile or higher, whereas the recorded 
incidence was 9% and 12% by customised and population 
centiles, respectively. This incidence is well below the 16% 
reported in UK women with similar BMI (range 
35·0–39·9 kg/m²),27 and roughly half of that noted in the 
LIMIT trial (20%), which included women who had a 
lower BMI.19 Our use of IADPSG criteria for diagnosis of 
gestational diabetes could partly explain the low incidence 
of large-for-gestational-age babies in our study. To our 
knowledge, no previous study of women with obesity has 
diagnosed gestational diabetes with these criteria, and a 
quarter of women in both groups in our trial had 
gestational diabetes. Only 9% would have had a diagnosis 
of gestational diabetes had we used the previous WHO 
guidelines.11 Diagnosis and treatment of more women 
with gestational diabetes in this study compared with 
current clinical practice in the UK could, therefore, account 
for the lower incidence of large-for-gestational-age infants 
to roughly population levels (10%). In line with this notion, 
a 50% reduction in large-for-gestational-age infants was 
reported after treatment of women with mild gestational 
diabetes28 that fell below conventional diagnostic thresholds 
but would have been treated by the new criteria. Women 
were treated according to local practice at trial centres, 83% 
receiving treatment after a diagnosis of gestational 
diabetes. Although local practice might have diﬀ ered, 
randomisation was minimised to centre, and variable 
practice is unlikely to have aﬀ ected primary trial outcomes. 
Indeed, had all women been treated, as recommended by 
the IADPSG, the incidence of large-for-gestational-age 
infants might have been reduced further. Universal testing 
of all participants in our study for gestational diabetes, 
independent of the diagnostic criteria, might have 
contributed to the diﬀ erence between trial and population 
incidences of large-for-gestational-age infants because, 
despite NICE recommendations, universal testing of 
women with obesity is not adopted across the UK.11
Several neonatal outcomes, including birthweight and 
inpatient days, were lower than UK outcomes for women 
with obesity,27 although caesarean section rates were 
similar, potentially a reﬂ ection of current management of 
women with a diagnosis of gestational diabetes. 
Participation in a clinical trial is in itself unlikely to be a 
cause of lower than anticipated incidence of large-
for-gestational-age infants because no evidence for such an 
eﬀ ect was noted in the LIMIT trial, in which the incidence 
of large-for-gestational-age infants was 20%.19 Comparison 
of the incidence of large-for-gestational-age infants with 
eligible women who declined participation was precluded 
because those with available birthweight data had a 
signiﬁ cantly lower BMI than did the group as a whole.
Our study highlights the need for randomised 
controlled trials in women with obesity that do universal 
testing and formally compare IADPSG and older 
diagnostic criteria for gestational diabetes. In the UK, 
comparison should be made with the most recent NICE 
criteria, which do not align with IADPSG.11
More infants born to mothers in the intervention group 
developed neonatal hypoglycaemia than did those in the 
standard care group, but statistical power for this outcome 
was low. This ﬁ nding contrasts with that of a meta-
analysis of smaller lifestyle intervention studies, which 
showed no eﬀ ect.6 Ten infants in the intervention group 
with hypoglycaemia were fed formula milk from birth, 
compared with two in the standard care group (37% vs 
16%; p=0·04). Since early introduction of formula feeding 
has been associated with neonatal hypo glycaemia,29 this 
factor could be contributory. The rates of exclusive 
breastfeeding (p=0·73) or formula feeding (p=0·63) did 
not diﬀ er at neonatal discharge between the two study 
groups; therefore, this ﬁ nding is likely to be attributable 
to chance.
The behavioural intervention we assessed in this study 
could provide a means to improve healthy behaviours in 
obese pregnant women. It oﬀ ers an alternative to current 
UK NICE guidelines,5 which recommend general healthy 
eating and physical activity for pregnant women with 
obesity with little evidence for proven change in behaviours. 
The potential beneﬁ t of the intervention on post-pregnancy 
infant health and on maternal and infant long-term health 
needs further investigation, which is under way. Increasing 
the intensity and duration of the intervention, which is 
already greater than that adopted in previous studies,6,17,19,23 
is likely to be impractical for most women with obesity.
The current focus on behavioural interventions to 
prevent gestational diabetes would seem to be misplaced. 
The intervention we assessed could be used as an 
evidence-based method to encourage healthy dietary and 
physical activity behaviours in women with obesity. 
However, eﬀ orts to prevent gestational diabetes should 
be diverted towards not only trials of targeted 
interventions, including pharmacotherapy but also 
establishing optimum diagnostic criteria for gestational 
diabetes to reduce risk of adverse outcomes. Importantly, 
renewed eﬀ orts are needed at the population level to 
prevent obesity in women of reproductive age.
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